Immune checkpoint inhibitors and prostate cancer: a new frontier?

Despite recent advances in the treatment of metastatic castrationresistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune ch...

Full description

Bibliographic Details
Main Authors: Alessandra Modena, Chiara Ciccarese, Roberto Iacovelli, Matteo Brunelli, Rodolfo Montironi, Michelangelo Fiorentino, Giampaolo Tortora, Francesco Massari
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-04-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/293